Trial Profile
A Non-Interventional Study of Bosutinib in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 28 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 10 Feb 2015 New trial record